The fda has granted breakthrough therapy designation to furmonertinib for use as a potential therapeutic option in patients with previously untreated, locally advanced or metastatic nonsquamous. A phase 1b study of furmonertinib, an oral, brain penetrant, selective egfr inhibitor, in patients with advanced nsclc with egfr exon 20 insertions Furmonertinib (ast2818) is an oral, brain penetrant, broadly.
Prime peachey - YouTube
